The International Menopause Society has created recommendations on women’s midlife health and menopause
hormone therapy to help guide health-care professionals in optimising their management of women in the menopause
transition and beyond. Venous thromboembolism events are the most prevalent adverse effect of oral
oestrogens in early postmenopausal women. The risk for serious venous thromboembolic events increases
with age (although rare in low-risk women until the age of 60 years) and is also positively associated with obesity
and thrombophilia. Epidemiological studies have not found any increased risk of VTE with the use of transdermal
oestrogen. There is also substantial evidence that the type of progestin associated with oestrogen is of importance.
The use of transdermal oestrogen related to progesterone might be safer regarding VTE, especially
in women at high VTE risk.